Supplementary figure S1. Flow diagram

Enrollment

Assessed for eligibility (n=85)
- Excluded (n=5)
  - Not meeting inclusion criteria (n=0)
  - Declined to participate (n=5)

Randomized (n=80)

Allocation

Allocated to the sitagliptin group (n=30)
- Received allocated intervention (n=30)
- Did not receive allocated intervention (n=0)

Allocated to the milaglibidine group (n=30)
- Received allocated intervention (n=30)
- Did not receive allocated intervention (n=0)

Follow-Up

Lost to follow-up (n=1)
- withdrew consent
Lost to follow-up (n=0)
- Discontinued intervention (n=1)
  - returned to insulin therapy in order to occur hyperglycemia

Lost to follow-up (n=0)
- Discontinued intervention (n=1)
  - subconjunctival hemorrhage

Analyzed (n=28)
- Excluded from analysis (n=0)

Analyzed (n=29)
- Excluded from analysis (n=0)
Supplemental figure S2. Insulin doses (A, B) Insulin dose per Body weight (C, D) and changes in HbA1c after the switch from a rapid-acting insulin analog.

A. sitagliptin group

B. mitiglinide group
C. sitagliptin group

D. mitiglinide group
Supplemental figure S3. CPI and changes in glycated hemoglobin (HbA1c) after the switch from a rapid-acting insulin analog.

A. sitagliptin group

B. mitiglinide group